Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | ESRRG | P62508 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | GBA1 | P04062 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL17262082 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4084 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 1.00 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL5789295 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL3794383 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4323848 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4323842 | 0.99 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102458404-A | Treatment of hot flashes, vasomotor symptoms and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECH INC | 2012-05-16 | — | — | CN | claimed |
| CN-1630516-A | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents | UAB RESEARCH FOUNDATION (US) | 2005-06-22 | — | — | CN | claimed |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-18 | — | — | US | disclosed |
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3730507-A1 | NICOTINOYL RIBOSIDE AND NICOTINAMIDE RIBOSIDE COMPOSITIONS FOR USE IN REDUCING TOXICITY INDUCED BY HMG-COA REDUCTASE INHIBITORS | Cornell Research Foundation, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | CORNELL UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| CN-110075097-A | Pharmaceutical preparation based on genotype or phenotype | 拜耳股份公司 | 2019-08-02 | — | — | CN | disclosed |
| US-20190192542-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| CN-109852671-A | The probabilistic Modeling assessment cell signaling pathway activity expressed using target gene | 皇家飞利浦有限公司 | 2019-06-07 | — | — | CN | disclosed |
| EP-1670942-A2 | GENETIC ANALYSIS FOR STRATIFICATION OF BREAST CANCER RISK | InterGenetics, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1620569-A2 | A FORWARD MUTATION ASSAY BASED ON 5-FLUOROURACIL RESISTANCE | Merck & Co., Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005024067-A2 | GENETIC ANALYSIS FOR STRATIFICATION OF BREAST CANCER RISK | INTERGENETICS, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| CN-1560002-A | Synthesizing compound of 1,1,2 triaromatic radical-1,3 butadiene kind by suzuki-miyaura coupling reaction | 中国科学院上海有机化学研究所 | 2005-01-05 | — | — | CN | disclosed |
| WO-2004096987-A2 | A FORWARD MUTATION ASSAY BASED ON 5-FLUOROURACIL RESISTANCE | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1159619-A2 | METHODS OF DIAGNOSING AND TREATING BREAST CANCER | EOS Biotechnology, Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000055629-A2 | METHODS OF DIAGNOSING AND TREATING BREAST CANCER | EOS BIOTECHNOLOGY, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
| EP-0616812-B1 | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | BERLEX BIOSCIENCES (US) | 1999-11-03 | — | — | EP | disclosed |
| EP-0616812-A1 | Combination with anti-hormonal compounds and binding molecules for the treatment of cancer | BERLEX BIOSCIENCES (US) | 1994-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077129-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | ESR1 3315/4885ESR2 3399/4885MAPT 3467/4885 |
| US-20190192542-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | ESR1 3315/4885ESR2 3399/4885MAPT 3467/4885 |
| US-20200289535-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | ESR1 3315/4885ESR2 3399/4885MAPT 3467/4885 |
| US-10668096-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | ESR1 3315/4885ESR2 3399/4885MAPT 3467/4885 |
| US-20210353657-A1 | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE | NNT, CD38, NAMPT | ESR1 3315/4885ESR2 3399/4885MAPT 3467/4885 |
| US-11633414-B2 | Nicotinoyl riboside compositions and methods of use | NNT, CD38, NAMPT | ESR1 3315/4885ESR2 3399/4885MAPT 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.